IMJUDO (AstraZeneca Pty Ltd)
Product name
IMJUDO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
219 (255 working days)
Active ingredients
tremelimumab
Registration type
NCE/NBE
Indication
Hepatocellular Carcinoma (HCC)
IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.